These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27440273)

  • 21. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.
    Wang HC; Li TY; Chao YJ; Hou YC; Hsueh YS; Hsu KH; Shan YS
    Clin Cancer Res; 2016 Jul; 22(14):3477-87. PubMed ID: 26936919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cathepsin L is highly expressed in gastrointestinal stromal tumors.
    Miyamoto K; Iwadate M; Yanagisawa Y; Ito E; Imai J; Yamamoto M; Sawada N; Saito M; Suzuki S; Nakamura I; Ohki S; Saze Z; Kogure M; Gotoh M; Omicronbara K; Ohira H; Tasaki K; Abe M; Goshima N; Watanabe S; Waguri S; Takenoshita S
    Int J Oncol; 2011 Nov; 39(5):1109-15. PubMed ID: 21769426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.
    Antonescu CR; Viale A; Sarran L; Tschernyavsky SJ; Gonen M; Segal NH; Maki RG; Socci ND; DeMatteo RP; Besmer P
    Clin Cancer Res; 2004 May; 10(10):3282-90. PubMed ID: 15161681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
    Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
    Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
    Rubin BP; Singer S; Tsao C; Duensing A; Lux ML; Ruiz R; Hibbard MK; Chen CJ; Xiao S; Tuveson DA; Demetri GD; Fletcher CD; Fletcher JA
    Cancer Res; 2001 Nov; 61(22):8118-21. PubMed ID: 11719439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.
    Ou WB; Ni N; Zuo R; Zhuang W; Zhu M; Kyriazoglou A; Wu D; Eilers G; Demetri GD; Qiu H; Li B; Marino-Enriquez A; Fletcher JA
    Oncogene; 2019 Sep; 38(39):6615-6629. PubMed ID: 31371779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.
    Rizzo FM; Palmirotta R; Marzullo A; Resta N; Cives M; Tucci M; Silvestris F
    BMC Cancer; 2016 Feb; 16():87. PubMed ID: 26867653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth.
    Bai CG; Hou XW; Wang F; Qiu C; Zhu Y; Huang L; Zhao J; Xu JJ; Ma DL
    World J Gastroenterol; 2012 Jun; 18(23):2929-37. PubMed ID: 22736916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
    Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
    Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.
    Ito T; Yamamura M; Hirai T; Ishikawa T; Kanda T; Nakai T; Ohkouchi M; Hashikura Y; Isozaki K; Hirota S
    Int J Clin Exp Pathol; 2014; 7(11):8024-31. PubMed ID: 25550846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors.
    Zhang Y; Gu ML; Zhou XX; Ma H; Yao HP; Ji F
    Oncol Rep; 2014 Sep; 32(3):927-34. PubMed ID: 24970355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M; Li DQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The GIST paradigm: how to establish diagnostic and prognostic criteria.
    Calabuig-Farinas S; Lopez-Guerrero JA; Llombart-Bosch A
    Arkh Patol; 2011; 73(4):13-21. PubMed ID: 22164425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.